|
|
MATK |
megakaryocyte-associated tyrosine kinase |
- Downregulation of ERBB2 signaling
|
|
|
|
|
MET |
MET proto-oncogene, receptor tyrosine kinase |
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Sema4D mediated inhibition of cell attachment and migration
- RAF/MAP kinase cascade
- MET Receptor Activation
- Negative regulation of MET activity
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates RAS signaling
- MET activates PI3K/AKT signaling
- MET activates PTPN11
- MET activates PTK2 signaling
- InlB-mediated entry of Listeria monocytogenes into host cell
- InlB-mediated entry of Listeria monocytogenes into host cell
- MET interacts with TNS proteins
- MET activates RAP1 and RAC1
- MET receptor recycling
- MET activates STAT3
- MECP2 regulates neuronal receptors and channels
|
- K-252a
- SGX-523
- 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide
- N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide
- 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide
- N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide
- 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
- AMG-208
- 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE
- Crizotinib
- Cabozantinib
- Capmatinib
- Fostamatinib
- Tivantinib
- Brigatinib
- Amuvatinib
|
- Renal cell carcinoma
- Cholangiocarcinoma
- Gastric cancer
|
|
|
MME |
membrane metalloendopeptidase |
- Metabolism of Angiotensinogen to Angiotensins
- Neutrophil degranulation
|
- Candoxatril
- Omapatrilat
- N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1'-Biphenyl-4-Ylmethyl)Propanoyl]Alanine
- Phosphoramidon
- N-(3-Phenyl-2-Sulfanylpropanoyl)Phenylalanylalanine
- [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala
- Daglutril
- 2-[(1S)-1-BENZYL-2-SULFANYLETHYL]-1H-IMIDAZO[4,5-C]PYRIDIN-5-IUM
- Thiorphan
- Sacubitril
- Candoxatrilat
|
|
|
|
MS4A1 |
membrane spanning 4-domains A1 |
|
- Rituximab
- Ibritumomab tiuxetan
- Tositumomab
- Ofatumumab
- Obinutuzumab
- Technetium Tc-99m nofetumomab merpentan
- Ocrelizumab
|
|
|
|
MS4A2 |
membrane spanning 4-domains A2 |
- Fc epsilon receptor (FCERI) signaling
- Fc epsilon receptor (FCERI) signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Role of LAT2/NTAL/LAB on calcium mobilization
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- FCERI mediated NF-kB activation
|
|
|
|
|
MUC1 |
mucin 1, cell surface associated |
- Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC)
- Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS)
- Defective GALNT12 causes colorectal cancer 1 (CRCS1)
- Dectin-2 family
- Interleukin-4 and Interleukin-13 signaling
- O-linked glycosylation of mucins
- Termination of O-glycan biosynthesis
|
|
|
|
|
NDFIP2 |
Nedd4 family interacting protein 2 |
|
|
|
|
|
NEDD9 |
neural precursor cell expressed, developmentally down-regulated 9 |
|
|
|
|
|
NMT1 |
N-myristoyltransferase 1 |
- Late Phase of HIV Life Cycle
- Inactivation, recovery and regulation of the phototransduction cascade
- Activation, myristolyation of BID and translocation to mitochondria
|
- (1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone
|
|
|
|
NPHS1 |
NPHS1 adhesion molecule, nephrin |
- Nephrin family interactions
- Nephrin family interactions
|
|
- Nephrotic syndrome and focal segmental glomerulosclerosis
|
|
|
PAG1 |
phosphoprotein membrane anchor with glycosphingolipid microdomains 1 |
- GAB1 signalosome
- Phosphorylation of CD3 and TCR zeta chains
|
|
|
|
|
PAK2 |
p21 (RAC1) activated kinase 2 |
- Nef and signal transduction
- Generation of second messenger molecules
- Regulation of PAK-2p34 activity by PS-GAP/RHG10
- Regulation of activated PAK-2p34 by proteasome mediated degradation
- Stimulation of the cell death response by PAK-2p34
- FCERI mediated MAPK activation
- FCERI mediated MAPK activation
- CD28 dependent Vav1 pathway
- Ephrin signaling
- Sema3A PAK dependent Axon repulsion
- Activation of RAC1
- VEGFA-VEGFR2 Pathway
- Smooth Muscle Contraction
- VEGFR2 mediated vascular permeability
- CD209 (DC-SIGN) signaling
- RHO GTPases activate PAKs
- RHO GTPases activate PAKs
- MAPK6/MAPK4 signaling
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
|
|
|
|
|
PDE4A |
phosphodiesterase 4A |
- DARPP-32 events
- G alpha (s) signalling events
|
- Caffeine
- Theophylline
- Dyphylline
- Enprofylline
- Dipyridamole
- Iloprost
- Oxtriphylline
- Amrinone
- Roflumilast
- Piclamilast
- Crisaborole
- Ibudilast
- Propentofylline
- Drotaverine
- (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one
- 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid
- Tofisopam
- Trapidil
|
|
|
|
PDE4D |
phosphodiesterase 4D |
- DARPP-32 events
- G alpha (s) signalling events
|
- Adenosine phosphate
- Caffeine
- Caffeine
- Dyphylline
- Iloprost
- Amrinone
- Roflumilast
- Piclamilast
- Rolipram
- 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol
- Zardaverine
- 1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- (S)-Rolipram
- Cilomilast
- (R)-Rolipram
- 3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- 1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- Crisaborole
- Ibudilast
- Tetomilast
- Exisulind
- (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one
- 3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
- 3-isobutyl-1-methyl-7H-xanthine
- 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid
- Trapidil
|
|
|
|
PECAM1 |
platelet and endothelial cell adhesion molecule 1 |
- Platelet degranulation
- Cell surface interactions at the vascular wall
- PECAM1 interactions
- Integrin cell surface interactions
- Platelet sensitization by LDL
- Neutrophil degranulation
|
|
|
|
|
PIK3CG |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
- GPVI-mediated activation cascade
- Synthesis of PIPs at the plasma membrane
- G beta:gamma signalling through PI3Kgamma
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
|
- Staurosporine
- Myricetin
- LY-294002
- Quercetin
- 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE
- XL765
- TG100-115
- 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE
- N-(5-{4-Chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide
- 5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- (5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE
- Wortmannin
- 1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- Duvelisib
- Fostamatinib
|
|
|
|
PILRB |
paired immunoglobin like type 2 receptor beta |
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
|
|
|
PLCG1 |
phospholipase C gamma 1 |
- ISG15 antiviral mechanism
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PLCG1 events in ERBB2 signaling
- DAG and IP3 signaling
- PLC-gamma1 signalling
- Synthesis of IP3 and IP4 in the cytosol
- Downstream signal transduction
- Generation of second messenger molecules
- Role of phospholipids in phagocytosis
- Role of phospholipids in phagocytosis
- PECAM1 interactions
- EGFR interacts with phospholipase C-gamma
- DAP12 signaling
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- Role of second messengers in netrin-1 signaling
- VEGFR2 mediated cell proliferation
- VEGFR2 mediated cell proliferation
- Constitutive Signaling by EGFRvIII
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Phospholipase C-mediated cascade; FGFR3
- Phospholipase C-mediated cascade; FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 point mutants in cancer
- RET signaling
- Activated NTRK2 signals through PLCG1
- Activated NTRK2 signals through PLCG1
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Activated NTRK3 signals through PLCG1
- Activated NTRK3 signals through PLCG1
- FCGR3A-mediated IL10 synthesis
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
|
|
|
|
|
PLCG2 |
phospholipase C gamma 2 |
- GPVI-mediated activation cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Synthesis of IP3 and IP4 in the cytosol
- Generation of second messenger molecules
- Role of phospholipids in phagocytosis
- DAP12 signaling
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- CLEC7A (Dectin-1) signaling
- CLEC7A (Dectin-1) signaling
- Dectin-2 family
- Dectin-2 family
- Erythropoietin activates Phospholipase C gamma (PLCG)
- FCGR3A-mediated IL10 synthesis
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
|
|
|
PPP1R15A |
protein phosphatase 1 regulatory subunit 15A |
- Downregulation of TGF-beta receptor signaling
- Response of EIF2AK1 (HRI) to heme deficiency
|
|
|